Identification of RCC1–LCK as a novel fusion gene in pediatric erythroid sarcoma. Issue 9 (30th June 2022)

• Record Type: Journal Article
• Authors: Oya, Satoru; Osone, Shinya; Yoshida, Masanori; Nishimoto, Sota; Taura, Yoshihiro; Yoshida, Hideki; Miyachi, Mitsuru; Inaba, Tohru; Konishi, Eiichi; Kato, Motohiro; Imamura, Toshihiko; Iehara, Tomoko
• Is Part Of: Pediatric blood & cancer. Volume 69:Issue 9(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-06-30
• Subjects: erythroid sarcoma -- fusion gene -- LCK -- leukemogenesis -- myeloid sarcoma; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29848
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Erythroid sarcoma is a very rare subtype of myeloid sarcoma with undetermined biological features. Here, we present an infant with a multifocal erythroid sarcoma, diagnosed because the tumor cells were positive for glycophorin A. After acute myeloid leukemia‐oriented chemotherapy and surgical resection followed by cord blood transplantation, he has successfully maintained complete remission without any late effects. Total transcriptome analysis of the tumor identified a novel fusion gene, RCC1–LCK, and high LCK expression levels, suggesting that LCK overexpression was involved in leukemogenesis in this case.